EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Host-directed novel mechanistic insights of doxorubicin reveal its efficacy against drug-resistant HSV-1 underscoring risks with oncolytic virotherapy

Pankaj Sharma, Divya Kapoor, Sudhanshu Kumar Singh, Xiang Shen, Chandrashekhar D Patil, Deepak Shukla

Drug Resistance Updates · 2026-05 · 86 · 101362

DOI: 10.1016/j.drup.2026.101362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2026-05. Verfasst von Pankaj Sharma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Herpesvirus 1, Human, Doxorubicin, Drug Resistance, Viral, Antiviral Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, National Eye Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Herpes simplex virus type 1 (HSV-1) infects approximately four billion people worldwide, and the emergence of drug-resistant strains has reduced the effectiveness of existing antivirals. Targeting host pathways exploited by HSV-1 represents an attractive strategy for developing resistance-refractory antivirals. METHODS: We evaluated the antiviral potential of doxorubicin, an FDA-approved anticancer drug, against HSV-1 using in vitro cell culture systems, an ex vivo porcine corneal model, and an in vivo murine ocular infection model. Viral replication, host signaling pathways, and combinatorial interactions with nucleoside analogs were systematically assessed. RESULTS: Doxorubicin potently inhibited HSV-1 replication at sub-cytotoxic concentrations by suppressing the host PI3K-AKT-mTOR signaling axis, a pathway required for viral entry and productive replication. Antiviral activity was observed against laboratory-adapted strains as well as clinical acyclovir-resistant HSV-1 isolates. Pharmacological modulation of PI3K-AKT signaling, pathway activation kinetics, and studies in doxorubicin-resistant cells confirmed a host-directed mechanism. Doxorubicin exhibited strong synergy with nucleoside analog antivirals, enabling dose reduction without loss of efficacy. While inhibition of PI3K-AKT signaling constrained productive replication of both wild-type and oncolytic HSV-1, these effects were context-dependent and relevant to therapeutic settings that rely on robust viral replication. CONCLUSIONS: This study identifies PI3K-AKT pathway inhibition as a novel host-directed antiviral mechanism underlying doxorubicin's activity against HSV-1, demonstrates its synergistic potential with nucleoside analogs, and provides mechanistic insight into raising concerns over oncolytic HSV-based therapies. Collectively, these findings highlight the potential of localized, host-targeted strategies for managing drug-resistant HSV-1 infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 1, HumanDoxorubicinDrug Resistance, ViralAntiviral AgentsHerpes SimplexOncolytic VirotherapyAnimalsVirus ReplicationHost-Directed TherapyHumansMiceSignal TransductionProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesSwineVero CellsChlorocebus aethiopsAcyclovir

Stichwörter der Autor:innen

Antiviral therapyDoxorubicinDrug repurposingHerpes simplex virus type 1 (HSV-1)Nucleoside analog synergyPI3K-AKT-mTOR pathway

Substanzen

DoxorubicinAntiviral AgentsProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesAcyclovir

Autor:innen und Institutionen

  • Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL, USA.
  • Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL, USA; Department of Microbiology and Immunology, University of Illinois Chicago, Chicago, IL, USA.
  • Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL, USA; Department of Bioengineering, University of Illinois at Chicago, Chicago, IL 60607, USA.
  • Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL, USA; Department of Microbiology and Immunology, University of Illinois Chicago, Chicago, IL, USA; Department of Bioengineerin…

Förderung

  • NEI NIH HHS
  • National Eye Institute
  • National Institutes of Health

Zitieren

APA

Sharma, P., Kapoor, D., Singh, S. K., Shen, X., Patil, C. D., & Shukla, D. (2026). Host-directed novel mechanistic insights of doxorubicin reveal its efficacy against drug-resistant HSV-1 underscoring risks with oncolytic virotherapy. Drug Resistance Updates, 86, 101362. https://doi.org/10.1016/j.drup.2026.101362

Vancouver

Sharma P, Kapoor D, Singh SK, Shen X, Patil CD, Shukla D. Host-directed novel mechanistic insights of doxorubicin reveal its efficacy against drug-resistant HSV-1 underscoring risks with oncolytic virotherapy. Drug Resistance Updates. 2026;86:101362. doi:10.1016/j.drup.2026.101362

BibTeX
@article{Sharma2026,
  author = {Sharma, Pankaj and Kapoor, Divya and Singh, Sudhanshu Kumar and Shen, Xiang and Patil, Chandrashekhar D and Shukla, Deepak},
  title = {Host-directed novel mechanistic insights of doxorubicin reveal its efficacy against drug-resistant HSV-1 underscoring risks with oncolytic virotherapy},
  journal = {Drug Resistance Updates},
  year = {2026},
  volume = {86},
  pages = {101362},
  doi = {10.1016/j.drup.2026.101362}
}
Kostenlos starten →